Effectiveness of the TYPHIBEV® (Vi-CRM197 conjugate) vaccine introduction in Nepal: A test-negative, case-control study
The findings indicate that TYPHIBEV® was highly effective in preventing typhoid fever over a 30-month follow-up period following national introduction, with effectiveness estimates comparable to those observed for Typbar-TCV®.
Authors
- Ram Hari Chapagain (ORCID: https://orcid.org/0000-0001-5939-5471)
- Dipesh Tamrakar (ORCID: https://orcid.org/0000-0002-7258-1436)
- Denise O. Garrett (ORCID: https://orcid.org/0000-0001-6411-3459)
- Isaac I. Bogoch (ORCID: https://orcid.org/0000-0003-1590-6748)
- Shivram Naga
- Rabin Sharma Pokharel
- Wirongrong Cheirakul
- Akhil Tamrakhar
- Manoj Mahato
- Basudha Shrestha
- Esther Jung
- Surendra Kumar Madhup
- Kate Doyle
- Stephen P. Luby
- Sabin Bikram Shahi
- Jason R. Andrews
- Pratibha Bista Roka
Institutions
- University of Toronto (CA)
- Mahidol University (TH)
- Bir Hospital (NP)
- Dhulikhel Hospital (NP)
- Kanti Children's Hospital (NP)
- Mahidol Oxford Tropical Medicine Research Unit (TH)
- Bhaktapur Cancer Hospital (NP)
- Sabin Vaccine Institute (US)
- Civil Service Hospital (NP)
- Kathmandu University (NP)
- Kathmandu Medical College Teaching Hospital (NP)
- Stanford University (US)
Publication Details
- Journal
- Journal of Infection
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1016/j.jinf.2026.106719
- Primary Topic
- Virology and Viral Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00